112522-64-2 | 4-Acetylamino-n-(2'-aminophenyl)benzamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$8.00	$6.00
10mg	98%	in stock	$20.00	$14.00
1g	98%	in stock	$272.00	$190.00

Description

• Catalog Number: AD40360
• Chemical Name: 4-Acetylamino-n-(2'-aminophenyl)benzamide
• CAS Number: 112522-64-2
• Molecular Formula: C15H15N3O2
• Molecular Weight: 269.2985
• MDL Number: MFCD00866266
• SMILES: CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N

Computed Properties

• Complexity: 351
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 3
• XLogP3: 1.3

Literature

• Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.

  Chemistry & biology 20120622

• Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.

  Carcinogenesis 20111001

• Interpreting clinical assays for histone deacetylase inhibitors.

  Cancer management and research 20110101

• Inside HDAC with HDAC inhibitors.

  European journal of medicinal chemistry 20100601

• Chemical phylogenetics of histone deacetylases.

  Nature chemical biology 20100301

• A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.

  Biochemical and biophysical research communications 20100205

• New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

  Journal of hematology & oncology 20090101

• The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

  Critical reviews in oncology/hematology 20081001

• Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.

  Journal of medicinal chemistry 20080710

• CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.

  Oncology reports 20080601

• Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

  Current medicinal chemistry 20080601

• Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

  Bioorganic & medicinal chemistry 20080315

• Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

  Bioorganic & medicinal chemistry letters 20080201

• Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.

  Journal of medicinal chemistry 20071115

• Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

  Oncology research 20050101

• A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041101

• Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma.

  Molecular cancer therapeutics 20030401

• Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.

  Cancer journal (Sudbury, Mass.) 20030101

• Latent hematopoietic stem cell toxicity associated with protracted drug administration.

  Experimental hematology 20010301

• Preclinical antitumor activity of CI-994.

  Investigational new drugs 19960101